Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion
chemotherapy of oxaliplatin and raltitrexed plus lenvatinib and camrelizumab in patients with
unresectable hepatocellular carcinoma (HCC).